Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma
Science Advances · 2025
DOI: 10.1126/sciadv.adr8841 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Zhi Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Beijing Institute of Technology, Beijing 100081, China. Hauptthemen laut MEDLINE: Glioblastoma, Peptides, Tumor-Associated Macrophages, Immunotherapy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The prevalent tumor-supporting glioblastoma-associated macrophages (GAMs) promote glioblastoma multiforme (GBM) progression and resistance to multiple therapies. Repolarizing GAMs from tumor-supporting to tumor-inhibiting phenotype may troubleshoot. However, sufficient accumulation of drugs at the GBM site is restricted by blood-brain barrier (BBB). Herein, we designed peptide-drug conjugates (PDCs) by conjugating camptothecin or resiquimod to a tandem peptide composed of matrix metalloproteinase 2–responsive peptide and angiopep-2 via disulfonyl-ethyl carbonate/carbamate ( MA PDCs). The mixed self-assembly MA PDCs could recognize low-density lipoprotein receptor–related protein 1 (LRP1) to facilitate BBB transport. Once reaching the GBM site, the responsive peptide would be cleaved to shed the angiopep-2, blocking abluminal LRP1-mediated brain-to-blood efflux and enhancing drug retention. Sequentially, drugs are released under the high level of intracellular glutathione. In vivo studies demonstrated that MA PDCs repolarized GAMs, boosted immune response, and resensitized chemotherapeutic toxicity, offering a much-improved anti-GBM effect. The effectiveness of MA PDCs validates GAMs as therapeutic target and PDCs as versatile brain delivery system with high design flexibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Life Science, Beijing Institute of Technology, Beijing 100081, China.
- Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing 100081, China.
- West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Zhi Li, Huile Gao, Yuanyu Huang, Shaobo Ruan
Zitieren
APA
Li, Z., Jiang, S., Wang, J., Li, W., Yang, J., Liu, W., Gao, H., Huang, Y., & Ruan, S. (2025). Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma. Science Advances. https://doi.org/10.1126/sciadv.adr8841
Vancouver
Li Z, Jiang S, Wang J, Li W, Yang J, Liu W, et al. Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma. Science Advances. 2025. doi:10.1126/sciadv.adr8841
BibTeX
@article{Li2025,
author = {Li, Zhi and Jiang, Shaoping and Wang, Jie and Li, Wenpei and Yang, Jun and Liu, Weimin and Gao, Huile and Huang, Yuanyu and Ruan, Shaobo},
title = {Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adr8841}
}
EUVIMED